SASB disclosure 2021
In 2021, we integrated our Sustainability Accounting Standards Board (SASB) disclosures into our Sustainability Report in 2021. In addition to our disclosures pursuant to the SASB standard “Biotechnology & Pharmaceuticals”, we reported our information for the “Medical Equipment & Supplies” and “Semiconductors” industries for the first time. We thus cover our three business sectors now. With our voluntary SASB disclosures, we want to meet the increasing demands of our investors and other stakeholders. The reported data provide transparent, financially material and meaningful information on sustainability. To meet the evolving interests and requirements of our stakeholders in the future as well, we will continuously develop and expand our SASB reporting.
The SASB disclosures were not part of the limited assurance engagement conducted by an independent auditor for our 2021 Sustainability Report.
Biotechnology & Pharmaceuticals
Safety of Clinical Trial Participants |
||||
HC-BP-210a.1 |
|
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials |
|
|
HC-BP-210a.2 |
|
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) |
|
There were no FDA Good Clinical Practice (GCP) sponsor inspections related to clinical trials in 2021. |
HC-BP-210a.3 |
|
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries |
|
Not reported |
Access to Medicines |
||||
HC-BP-240a.1 |
|
Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index |
|
|
HC-BP-240a.2 |
|
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) |
|
Currently there is no product on the list. |
Affordability & Pricing |
||||
HC-BP-240b.1 |
|
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period |
|
Not reported |
HC-BP-240b.2 |
|
Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year |
|
The following overview shows the percentage change in the average list price (WAC) of our Healthcare US product portfolio compared to the previous year:
|
|
|
|
|
See also: Prices of medicines |
HC-BP-240b.3 |
|
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year |
|
We only report the percentage change in average list price across our U.S. product portfolio. The largest increase compared with the previous year amounted to 7.4% (Gonal-f® and Ovidrel®). |
Drug Safety |
||||
HC-BP-250a.1 |
|
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database |
|
Safety information and adverse event reporting program (FDA website) |
HC-BP-250a.2 |
|
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System |
|
Adverse event reporting system (FAERS) public dashboard (FDA website) |
HC-BP-250a.3 |
|
Number of recalls issued, total units recalled |
|
In 2021 we had three drug product recalls in total. None of these recalls was global; they affected individual countries only. None of the recalls was related to the USA. None of the recalls was related to serious injury or fatality, all were either Class II or III. According to our internal policies, any recall type is reported and discussed with the relevant national regulatory authority, including the U.S. FDA. All recall processes are managed under a Global Standard Procedure “Product Recall and Withdrawal Management” which is applied worldwide for medicinal products (pharmaceutical prescription, biological) and devices. |
HC-BP-250a.4 |
|
Total amount of product accepted for take-back, reuse, or disposal |
|
We do not take back products for reuse. In line with legal requirements in each country we take back products for disposal. |
HC-BP-250a.5 |
|
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type |
|
We had no such FDA enforcement actions in 2021. |
Counterfeit Drugs |
||||
HC-BP-260a.1 |
|
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting |
|
|
HC-BP-260a.2 |
|
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products |
|
We have implemented processes and procedures to ensure that all suspected counterfeit medicines are assessed by a team of experts. The scope of any notification that we provide is the outcome of strategic alignment between relevant functions (e.g. Medical, Procurement, Legal, Quality, Corporate Security, Regulatory Affairs, Communications). Levels of details and format of any notification, including the HA information and collaboration, dedicated patient communication, information/ |
HC-BP-260a.3 |
|
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products |
|
|
Ethical Marketing |
||||
HC-BP-270a.1 |
|
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims |
|
Not reported |
HC-BP-270a.2 |
|
Description of code of ethics governing promotion of off-label use of products |
|
|
Employee Recruitment, Development & Retention |
||||
HC-BP-330a.1 |
|
Discussion of talent recruitment and retention efforts for scientists and research and development personnel |
|
Leading and developing employees |
HC-BP-330a.2 |
|
|
||
Supply Chain Management |
||||
HC-BP-430a.1 |
|
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients |
|
Our Healthcare business sector does not participate in the Rx-360 International Pharmaceutical Supply Chain Consortium. However, our facilities are frequently audited by the respective health authorities of the countries in which we distribute our healthcare products. |
Business Ethics |
||||
HC-BP-510a.1 |
|
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery |
|
Not reported |
HC-BP-510a.2 |
|
Description of code of ethics governing interactions with health care professionals |
|
Our Code of Conduct presents and explains our company’s values and our ethical integrity standards (e.g. “We cannot be bribed, and we do not offer bribes”, “We make our cooperation with healthcare partners transparent”, among many others). It is complemented by our Global Anti-Corruption Policy, which stipulates that all business activities must be conducted in line with legally applicable anti-corruption standards. |
Activity metrics |
||||
HC-BP-000.A |
|
Number of patients treated |
|
In 2021, our Healthcare medicines were used to treat around 92 million patients. Additionally, we donated 182 million praziquantel tablets, enough to treat schistosomiasis in 73 million school-aged children in 2021. |
HC-BP-000.B |
|
Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3) |
|
Healthcare portfolio |
Medical Equipment & Supplies
Affordability & Pricing |
||||
HC-MS-240a.1 |
|
Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index |
|
Not reported |
HC-MS-240a.2 |
|
Description of how price information for each product is disclosed to customers or to their agents |
|
|
Product Safety |
||||
HC-MS-250a.1 |
|
Number of recalls issued, total units recalled |
|
We conduct monthly reviews of key performance quality indicators which include a review of multiple quality metrics including number of recalls. Quarterly trends are evaluated and reported through management reviews. |
HC-MS-250a.2 |
|
List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database |
|
In 2021, there were no Life Science products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database. |
HC-MS-250a.3 |
|
Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience database |
|
In 2021, there were no fatalities related to our Life Science products reported to the FDA Manufacturer and User Facility Device Experience database. |
HC-MS-250a.4 |
|
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type |
|
Life Science received three U.S. FDA 483 forms in 2021. |
Ethical Marketing |
||||
HC-MS-270a.1 |
|
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims |
|
Not reported |
HC-MS-270a.2 |
|
Description of code of ethics governing promotion of off-label use of products |
|
Before any products can be purchased from our Life Science platform, we use a customer screening process to guard against the purchase of our products for illegal purposes. Core steps of this process cover data sourcing, hazard assessment, safe-use/risk assessment and labels/safety data sheets. Besides our own process, we cooperate with responsible authorities in the U.S. (FBI and the Bureau of Alcohol, Tobacco, Firearms and Explosives, ATF), as well as international authorities (Interpol). |
Product Design & Lifecycle Management |
||||
HC-MS-410a.1 |
|
Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products |
|
We assess environmental, human health, and further sustainability aspects of chemical products that we are sourcing and/or producing and selling. |
HC-MS-410a.2 |
|
Total amount of products accepted for take-back and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies |
|
Since 2013, we have been partnering with Seeding Labs, a non-profit organization dedicated to equipping scientists in resource-limited countries with scientific equipment and support. In 2021, we donated 1,626 items of scientific equipment valued at more than $360,000. |
Supply Chain Management |
||||
HC-MS-430a.1 |
|
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality |
|
As a major supplier to the pharmaceutical industry, our Life Science business participates in the Rx-360 audit program. The Life Science facilities are regularly audited by customers and respective health authorities for regulated products. |
HC-MS-430a.2 |
|
Description of efforts to maintain traceability within the distribution chain |
|
Product safety (Life Science) |
HC-MS-430a.3 |
|
Description of the management of risks associated with the use of critical materials |
|
|
Business Ethics |
||||
HC-MS-510a.1 |
|
Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption |
|
Not reported |
HC-MS-510a.2 |
|
Description of code of ethics governing interactions with health care professionals |
|
Responsible interactions with healthcare systems |
Activity metrics |
||||
HC-MS-000.A |
|
Number of units sold by product category |
|
Not reported |
Semiconductors
Greenhouse Gas Emissions |
||||
TC-SC-110a.1 |
|
(1) Gross global Scope 1 emissions |
|
|
|
(2) amount of total emissions from perfluorinated compounds |
|
Not reported |
|
TC-SC-110a.2 |
|
Discussion of long-term and short-term strategy or plan to manage Scope 1 emissions, emissions reduction targets, and an analysis of performance against those targets |
|
|
Energy Management in Manufacturing |
||||
TC-SC-130a.1 |
|
(1) Total energy consumed |
|
|
|
(2) percentage grid electricity |
|
Not reported |
|
|
(3) percentage renewable |
|
||
Water Management |
||||
TC-SC-140a.1 |
|
(1) Total water withdrawn |
|
|
|
(2) total water consumed, percentage of each in regions with High or Extremely High Baseline Water Stress |
|
||
Waste Management |
||||
TC-SC-150a.1 |
|
Amount of hazardous waste from manufacturing, percentage recycled |
|
|
Employee Health & Safety |
||||
TC-SC-320a.1 |
|
Description of efforts to assess, monitor, and reduce exposure of employees to human health hazards |
|
|
TC-SC-320a.2 |
|
Total amount of monetary losses as a result of legal proceedings associated with employee health and safety violations |
|
Not reported |
Recruiting & Managing a Global & Skilled Workforce |
||||
TC-SC-330a.1 |
|
Percentage of employees that are |
|
|
|
(2) located offshore |
|
||
Product Lifecycle Management |
||||
TC-SC-410a.1 |
|
Percentage of products by revenue that contain IEC 62474 declarable substances |
|
Not reported |
TC-SC-410a.2 |
|
Processor energy efficiency at a system-level for: (1) servers, |
|
Not applicable |
|
|
Not applicable |
||
|
(3) laptops |
|
Not applicable |
|
Materials Sourcing |
||||
TC-SC-440a.1 |
|
Description of the management of risks associated with the use of critical materials |
|
Research & Development (Electronics) |
Intellectual Property Protection & Competitive Behavior |
||||
TC-SC-520a.1 |
|
Total amount of monetary losses as a result of legal proceedings associated with anti-competitive behavior regulations |
|
Not reported |
Activity metrics |
||||
TC-SC-000.A |
|
Total production |
|
Not reported |
TC-SC-000.B |
|
Percentage of production from owned facilities |
|
Not reported |